Trans-heterozygosity for mutations enhances the risk of recurrent/chronic pancreatitis in patients with Cystic Fibrosis

Background Recurrent (RP) and chronic pancreatitis (CP) may complicate Cystic Fibrosis (CF). It is still unknown if mutations in genes involved in the intrapancreatic activation of trypsin (IPAT) or in the pancreatic secretion pathway (PSP) may enhance the risk for RP/CP in patients with CF. Methods...

Full description

Saved in:
Bibliographic Details
Published inMolecular medicine (Cambridge, Mass.) Vol. 24; no. 1; pp. 38 - 10
Main Authors Sofia, Valentina Maria, Surace, Cecilia, Terlizzi, Vito, Da Sacco, Letizia, Alghisi, Federico, Angiolillo, Antonella, Braggion, Cesare, Cirilli, Natalia, Colombo, Carla, Di Lullo, Antonella, Padoan, Rita, Quattrucci, Serena, Raia, Valeria, Tuccio, Giuseppe, Zarrilli, Federica, Tomaiuolo, Anna Cristina, Novelli, Antonio, Lucidi, Vincenzina, Lucarelli, Marco, Castaldo, Giuseppe, Angioni, Adriano
Format Journal Article
LanguageEnglish
Published London BioMed Central 27.07.2018
Springer Nature B.V
BMC
Subjects
Online AccessGet full text
ISSN1076-1551
1528-3658
1528-3658
DOI10.1186/s10020-018-0041-6

Cover

More Information
Summary:Background Recurrent (RP) and chronic pancreatitis (CP) may complicate Cystic Fibrosis (CF). It is still unknown if mutations in genes involved in the intrapancreatic activation of trypsin (IPAT) or in the pancreatic secretion pathway (PSP) may enhance the risk for RP/CP in patients with CF. Methods We enrolled: 48 patients affected by CF complicated by RP/CP and, as controls 35 patients with CF without pancreatitis and 80 unrelated healthy subjects. We tested a panel of 8 genes involved in the IPAT, i.e. PRSS1, PRSS2, SPINK1, CTRC, CASR, CFTR, CTSB and KRT8 and 23 additional genes implicated in the PSP. Results We found 14/48 patients (29.2%) with mutations in genes involved in IPAT in the group of CF patients with RP/CP, while mutations in such genes were found in 2/35 (5.7%) patients with CF without pancreatitis and in 3/80 (3.8%) healthy subjects ( p  < 0.001). Thus, we found mutations in 12 genes of the PSP in 11/48 (22.9%) patients with CF and RP/CP. Overall, 19/48 (39.6%) patients with CF and RP/CP showed one or more mutations in the genes involved in the IPAT and in the PSP while such figure was 4/35 (11.4%) for patients with CF without pancreatitis and 11/80 (13.7%) for healthy controls ( p  < 0.001). Conclusions The trans-heterozygous association between CFTR mutations in genes involved in the pathways of pancreatic enzyme activation and the pancreatic secretion may be risk factors for the development of recurrent or chronic pancreatitis in patients with CF.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1076-1551
1528-3658
1528-3658
DOI:10.1186/s10020-018-0041-6